Skip to main content
OTCMKTS:KALTF

Claritas Pharmaceuticals Stock Forecast, Price & News

$0.03
0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.03
▼
$0.03
50-Day Range
$0.03
▼
$0.06
52-Week Range
$0.00
▼
$0.25
Volume232,343 shs
Average Volume1.03 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KALTF News and Ratings via Email

Sign-up to receive the latest news and ratings for Claritas Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Claritas Pharmaceuticals logo

About Claritas Pharmaceuticals

Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. The company was founded in 2014 and is headquartered in San Rafael, California.

Headlines

Claritas Pharmaceuticals Issues Letter to Shareholders
Claritas Pharmaceuticals Issues Letter to Shareholders
May 11, 2021 |  finance.yahoo.com
KALTF
KALTF
May 6, 2021 |  seekingalpha.com
Kalytera Therapeutics, Inc. (OTCMKTS:KALTF) Short Interest Down 95.8% in April
Kalytera Therapeutics, Inc. (OTCMKTS:KALTF) Short Interest Down 95.8% in April
April 28, 2021 |  americanbankingnews.com
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
April 21, 2021 |  finance.yahoo.com
Kalytera Therapeutics (OTCMKTS:KALTF) Shares Pass Below Fifty Day Moving Average of $0.04
Kalytera Therapeutics (OTCMKTS:KALTF) Shares Pass Below Fifty Day Moving Average of $0.04
April 21, 2021 |  americanbankingnews.com
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients
April 8, 2021 |  finance.yahoo.com
Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc.
Kalytera Therapeutics Inc. Completes Name Change to Claritas Pharmaceuticals, Inc.
April 2, 2021 |  finance.yahoo.com
Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107
Claritas Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107
April 1, 2021 |  finance.yahoo.com
Claritas Announces Addition of Perenlei Enkhbaatar, M.D., Ph.D., FAHA to the Company’s Board of Directors
Claritas Announces Addition of Perenlei Enkhbaatar, M.D., Ph.D., FAHA to the Company’s Board of Directors
March 26, 2021 |  finance.yahoo.com
Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors
Claritas Announces Appointment of Robert Farrell, J.D. as Chairman of the Company’s Board of Directors
March 18, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:KALTF
Previous SymbolOTCMKTS:QUEZF
CUSIPN/A
CIKN/A
Webkalytera.co
Phone888-861-2008
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank™

Overall MarketRank™

0.58 out of 5 stars

Medical Sector

1426th out of 2,044 stocks

Biotechnology Industry

72nd out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Claritas Pharmaceuticals (OTCMKTS:KALTF) Frequently Asked Questions

What stocks does MarketBeat like better than Claritas Pharmaceuticals?

Wall Street analysts have given Claritas Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Claritas Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Claritas Pharmaceuticals?

Claritas Pharmaceuticals saw a decrease in short interest in April. As of April 15th, there was short interest totaling 7,000 shares, a decrease of 95.8% from the March 31st total of 167,800 shares. Based on an average daily volume of 390,200 shares, the short-interest ratio is presently 0.0 days.
View Claritas Pharmaceuticals' Short Interest.

How were Claritas Pharmaceuticals' earnings last quarter?

Claritas Pharmaceuticals, Inc. (OTCMKTS:KALTF) released its earnings results on Friday, November, 29th. The company reported ($0.02) earnings per share (EPS) for the quarter.
View Claritas Pharmaceuticals' earnings history.

How has Claritas Pharmaceuticals' stock price been impacted by Coronavirus?

Claritas Pharmaceuticals' stock was trading at $0.0219 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KALTF stock has increased by 43.4% and is now trading at $0.0314.
View which stocks have been most impacted by COVID-19.

Who are Claritas Pharmaceuticals' key executives?

Claritas Pharmaceuticals' management team includes the following people:
  • Mr. Robert Farrell J.D., Chairman, CEO & Pres
  • Ms. Victoria Diana Rudman, Interim CFO, Treasurer & Sec. (Age 53, Pay $75k)
  • Dr. Sari Prutchi-Sagiv Ph.D., Chief Scientific Officer
  • Dr. Moshe Yeshurun M.D., Chief Medical Officer
  • Mr. Seth Yakatan, Co-Founder (Age 51)
  • Dr. Stuart L. Silverman, Co-Chair of Scientific Advisory Board and VP of Medical Affairs (Age 74)

Who are some of Claritas Pharmaceuticals' key competitors?

Some companies that are related to Claritas Pharmaceuticals include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF) and Almirall (LBTSF).
View all of KALTF's competitors.

What is Claritas Pharmaceuticals' stock symbol?

Claritas Pharmaceuticals trades on the OTCMKTS under the ticker symbol "KALTF."

How do I buy shares of Claritas Pharmaceuticals?

Shares of KALTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Claritas Pharmaceuticals' stock price today?

One share of KALTF stock can currently be purchased for approximately $0.03.

What is Claritas Pharmaceuticals' official website?

The official website for Claritas Pharmaceuticals is kalytera.co.

How can I contact Claritas Pharmaceuticals?

The company can be reached via phone at 888-861-2008.


This page was last updated on 5/15/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.